Presents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies
The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science.
Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T).
Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also:
- Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biology
- Focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms
- Covers FDA-approved drugs and their indications, as well as drugs currently in development
- Provides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacy
- Includes boxed sections highlighting major unique points about the information in the chapter
Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.
OWEN A. O’CONNOR, MD, PhD, American Cancer Society Research Professor; Professor of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA.
STEPHEN M. ANSELL, MD, PhD, Consultant, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
JOHN G. GRIBBEN, MD, DSc, Hamilton-Fairley Chair of Medical Oncology, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK.
